A Case Study of Atrial Fibrillation Induced by Utidelone in Palliative Chemotherapy for Metastatic Breast Cancer - Takeaways - MDSpire

A Case Study of Atrial Fibrillation Induced by Utidelone in Palliative Chemotherapy for Metastatic Breast Cancer

  • By

  • Qihuan Shen

  • Yuhao Huang

  • Haoran Li

  • Baoying Chen

  • Huadi Shi

  • Zumin Xu

  • April 29, 2026

  • 0 min

Share

  • 1

    A 57-year-old male with metastatic breast cancer developed atrial fibrillation during utidelone infusion for palliative chemotherapy.

  • 2

    Prior to treatment, all cardiological examinations were normal, with no evidence of cardiovascular disease or thyroid dysfunction.

  • 3

    Utidelone, approved in 2021, has not prominently reported cardiotoxicity, raising concerns about its potential proarrhythmic effects.

  • 4

    The patient experienced sudden-onset arrhythmia 24 hours post-infusion, indicating a possible link between utidelone and atrial fibrillation.

  • 5

    This case underscores the necessity for careful cardiac monitoring during chemotherapy with innovative agents like utidelone.

Original Source(s)

A Case Study of Atrial Fibrillation Induced by Utidelone in Palliative Chemotherapy for Metastatic Breast Cancer

  • by Qihuan Shen, Yuhao Huang, Haoran Li, Baoying Chen, Huadi Shi, Zumin Xu

  • April 29, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases